

REMARKS

The Claims in the case are Claims 1, 2, 12, and 20-25. Claims 1, 2, and 12 have been allowed.

Claims 20-25 are rewritten versions of the process claims 3-11. Claims 20, 21 and 22 generally correspond to Claims 8, 10 and 11. Claims 23, 24, and 25 generally correspond to Claims 3, 10, and 11. The Claims also replace Claims 14-19 in the amendment filed 4 June; the latter have been rewritten to clarify the ratio of the reactants to the amount of the solvents. The Claim revisions are to avoid the rejection of the Claims under Section 112, both 1st and 2nd paragraphs. The claims particularly point out and distinctly claim the subject matter pertaining to the key step of the crystallization. Support for the amounts of the solvents is found in the specification at p. 5, lines 10-27, as well as the Examples.

The other items in the amendment filed 4 June are maintained.

Reconsideration of the rejection is respectfully requested.


Should the Office feel that telephonic communication with Applicants' representative would further the prosecution of the instant application, the examiner is invited to telephone the undersigned.

Early and favorable action on the merits is earnestly solicited.

No fees are believed due with this paper, if any are in fact due, please charge them to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7903
30950supplemental amend
Date: June 10, 2003

Respectfully submitted,



Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640